PostScript

MATTERS ARISING

Systemic inflammation in osteoarthritis

Several studies have shown that the acute phase response may take place in osteoarthritis (OA), suggesting that low grade systemic inflammation may be present in patients with OA.1–4 I read with interest the paper by Stürmer et al. on high sensitivity C reactive protein (CRP) in relation to the severity and extent of OA.5 As assessed by high sensitivity nephelometry, serum high sensitivity CRP was higher in 770 patients with advanced OA than in 367 age and sex matched healthy controls (geometric mean 2.5 mg/l v 1.7 mg/l, respectively). Moreover, severity of pain as measured by a visual analogue scale was associated with mean high sensitivity CRP. Interestingly, neither the bilateral nor the generalised extent of OA, nor any of the dimensions of the Western Ontario and McMaster University OA index (WOMAC) were associated with mean high sensitivity CRP concentrations. The authors concluded that the subjective severity of pain is associated with low level systemic inflammation in OA, and measurement of high sensitivity CRP may have some potential for monitoring and/or predicting the clinical course of OA.

In contrast with CRP, some acute phase proteins like α1-acid glycoprotein (AGP) or α1-antichymotrypsin (ACT) are glycoproteins and possess glycosylation sites attached by N-glycosidically bound, complex-type oligosaccharide side chains.1 Heteroglycans of acute phase proteins share the common core structure but differ in their outer chain sequences. According to the number of these oligosaccharide chains bi-, tri- and tetra-antennary heteroglycans can be distinguished. This structural diversity (termed “microheterogeneity”) results in different reactivity with the lectin concanavalin A (con A). It has been shown that biantennary side chains react strongly with con A. Thus, diverse microheterogeneous forms of acute phase glycoproteins, containing different number of biantennary heteroglycans, differ in their reactivity with con A.1 Glycosylation of acute phase proteins takes place in the liver and is controlled by cytokines.6

Affinity immunoelectrophoresis with con A is a simple technique that can be used to study the glycosylation pattern of acute phase proteins.7 Glycosylation variants of AGP/ACT can be separated during electrophoresis in a gel containing con A, and the area enclosed by the precipitates representing microheterogeneous variants of AGP and ACT can be measured by planimetry (fig 1). The results are usually expressed as the reactivity coefficients (AGP RC and ACT RC, respectively), calculated according to the formula: total area under the peaks of the con A reactive variants divided by the area enclosed by the peak representing the con A non-reactive variant.

Using affinity immunoelectrophoresis, we studied the systemic inflammatory response in 61 patients with OA classified as having clinically active (patients with rest joint pain, tenderness, joint swelling or effusion, n = 37) and clinically non-active (patients with radiological evidence of OA with no or mild clinical symptoms, n = 24) disease.8 In contrast with the study by Stürmer et al., patients with advanced OA and severe deformities were not included.

We found a significant decrease in the reactivity of AGP and ACT with con A in patients with clinically active OA in comparison with 24 patients with clinically non-active disease (p<0.001 and p<0.05 for AGP RC and ACT RC, respectively, fig 2). Concentrations of AGP, ACT, and low sensitivity CRP did not differ significantly between the groups. Serum concentrations of interleukin (IL) 1β, IL 6, and tumour necrosis factor α (TNFα) were either undetectable or low. However, in six of the seven synovial fluids available, IL6 concentrations were higher than in the respective serum samples. For TNFα the same could be shown in one case only.

Our findings suggest that there are changes in the microheterogeneity of acute phase glycoproteins in OA similar to those seen in rheumatoid arthritis and other chronic inflammatory conditions.9 As glycosylation of acute phase proteins does not depend on the expression of genes encoding the polypeptide chains of these proteins,9 glycosylation of acute phase glycoproteins may possibly be more sensitive to the cytokine control than their synthesis. Thus, even small fluctuations in the serum profile of cytokines might eventually lead to alterations in the microheterogeneity of acute phase glycoproteins, while having no apparent influence on their serum concentration. Our data suggest that determination of microheterogeneity of acute phase glycoproteins may help to determine systemic inflammatory activity in OA and may possibly be more sensitive than measurement of serum concentration of acute phase proteins, including high sensitivity CRP.

P Z Hrycaj
Department of Rheumatology and Clinical Immunology, University of Medical Sciences, Poznan, Poland

Correspondence to: Dr P Z Hrycaj, Department of Rheumatology and Clinical Immunology, University of Medical Sciences, Wroclaw 1, 61-626 Poznan, Poland; phrycaj@ipopnet.pl

References

Infliximab efficiency and failure

I would like to comment on an interesting letter in the *Annals* about anti-tumour necrosis factor (TNF) monotherapy for giant cell arteritis (GCA). The suggestion that vasculitis may be cured by anti-TNF treatment seems to be reasonable. The factors sustaining autoimmunity inflammation may include new target antigen production, immune system activation, and a vicious cycle of lymphocyte activation, and a vicious cycle of lymphocyte target antigen production, immune system cascade activation. This mechanism has been recently suggested after a report of long term remission (6–24 months) of Wegener’s granulomatosis as a result of infliximab treatment. Unfortunately, it is not relevant in this case.

The authors considered overcoming infliximab failure with an increased dose and frequency, but “such an approach is by no means cost effective and should not be attempted”. There is another way of dealing with a loss of infliximab efficiency, which may be explained by examining the background of human anti-tumour necrosis (HACA). The following information should be considered:

- Second line treatment should be added at the start of infliximab treatment to prevent HACA production.
- HACA may be related to a shortened duration of response after repeated infliximab doses as was first described in patients with rheumatoid arthritis (RA).
- The assay used to determine HACA is affected by the presence of infliximab itself, and HACA levels have to be measured after the drug has been stopped. In the ATTRACT study, 27 patients who discontinued infliximab treatment were tested for the presence of HACA: three (11%) were positive, two with a titre of 1/10 and one with a titre of 1/40.
- Formation of HACA may be inversely related to the infliximab dose. HACA were found in 53, 21, and 7% of patients with infliximab doses as was first described in patients with rheumatoid arthritis (RA).
- The assay used to determine HACA is affected by the presence of infliximab itself, and HACA levels have to be measured after the drug has been stopped. In the ATTRACT study, 27 patients who discontinued infliximab treatment were tested for the presence of HACA: three (11%) were positive, two with a titre of 1/10 and one with a titre of 1/40.
- Formation of HACA may be inversely related to the infliximab dose. HACA were found in 53, 21, and 7% of patients with infliximab doses as was first described in patients with rheumatoid arthritis (RA).
- The assay used to determine HACA is affected by the presence of infliximab itself, and HACA levels have to be measured after the drug has been stopped. In the ATTRACT study, 27 patients who discontinued infliximab treatment were tested for the presence of HACA: three (11%) were positive, two with a titre of 1/10 and one with a titre of 1/40.
- Formation of HACA may be inversely related to the infliximab dose. HACA were found in 53, 21, and 7% of patients with infliximab doses as was first described in patients with rheumatoid arthritis (RA).
- The assay used to determine HACA is affected by the presence of infliximab itself, and HACA levels have to be measured after the drug has been stopped. In the ATTRACT study, 27 patients who discontinued infliximab treatment were tested for the presence of HACA: three (11%) were positive, two with a titre of 1/10 and one with a titre of 1/40.
- Formation of HACA may be inversely related to the infliximab dose. HACA were found in 53, 21, and 7% of patients with infliximab doses as was first described in patients with rheumatoid arthritis (RA).
- The assay used to determine HACA is affected by the presence of infliximab itself, and HACA levels have to be measured after the drug has been stopped. In the ATTRACT study, 27 patients who discontinued infliximab treatment were tested for the presence of HACA: three (11%) were positive, two with a titre of 1/10 and one with a titre of 1/40.
- Formation of HACA may be inversely related to the infliximab dose. HACA were found in 53, 21, and 7% of patients with infliximab doses as was first described in patients with rheumatoid arthritis (RA).
- The assay used to determine HACA is affected by the presence of infliximab itself, and HACA levels have to be measured after the drug has been stopped. In the ATTRACT study, 27 patients who discontinued infliximab treatment were tested for the presence of HACA: three (11%) were positive, two with a titre of 1/10 and one with a titre of 1/40.
- Formation of HACA may be inversely related to the infliximab dose. HACA were found in 53, 21, and 7% of patients with infliximab doses as was first described in patients with rheumatoid arthritis (RA).
- The assay used to determine HACA is affected by the presence of infliximab itself, and HACA levels have to be measured after the drug has been stopped. In the ATTRACT study, 27 patients who discontinued infliximab treatment were tested for the presence of HACA: three (11%) were positive, two with a titre of 1/10 and one with a titre of 1/40.
- Formation of HACA may be inversely related to the infliximab dose. HACA were found in 53, 21, and 7% of patients with infliximab doses as was first described in patients with rheumatoid arthritis (RA).
- The assay used to determine HACA is affected by the presence of infliximab itself, and HACA levels have to be measured after the drug has been stopped. In the ATTRACT study, 27 patients who discontinued infliximab treatment were tested for the presence of HACA: three (11%) were positive, two with a titre of 1/10 and one with a titre of 1/40.
- Formation of HACA may be inversely related to the infliximab dose. HACA were found in 53, 21, and 7% of patients with infliximab doses as was first described in patients with rheumatoid arthritis (RA).
- The assay used to determine HACA is affected by the presence of infliximab itself, and HACA levels have to be measured after the drug has been stopped. In the ATTRACT study, 27 patients who discontinued infliximab treatment were tested for the presence of HACA: three (11%) were positive, two with a titre of 1/10 and one with a titre of 1/40.
present. Eight weeks after the last of 5×3 mg kg doses, serum concentrations of infliximab were 2 and <0.1 mg/l in those receiving concomi- tant MTX and those not.9b Clinical course declines rapidly after serum infliximab concentra- tions drop below 1 mg/l.10 The mean serum concentration in patients receiving the recommended dosage regimen of infliximab 3 mg/kg at weeks 0, 2, and 6 and every 8 weeks thereafter was 1.5 mg/l at week 30 (that is, 8 weeks after the last dose). Moreover, the rates of formation of HACA were 15, 7, and 0% with the 1, 3, and 10 mg/kg doses in those receiving concurrent MTX.10 Positivity, MTX, by decreasing the immunogenic potential of infliximab, may slow its rate of clearance from the blood. The clinical response rate achieved with infliximab 1–10 mg/kg in combination with MTX was consistently greater than that achieved with infliximab alone.

An HACA-reactive discontinuous epitope has recently been developed in order to create a functional mutant which has significantly reduced reactivity with the sera of patients with HACA after treatment.10 The technique is a valuable tool for identifying and adapting undesirable immunogenic sites on protein therapeutic agents.

With HACA, antibodies to another anti-TNF drug etanercept (Enbrel) are rarely found (2–4%) and, as they are non-neutralising they do not interfere with the efficiency of etanercept as monotherapy for at least 1 year. The reason for these differences is still unclear. Lower immunogenicity of the receptor-fusion protein may be implied.

Finally, it seems to me that one cannot define GCA as a self limiting disease, unlike polymyalgia rheumatica, as it may have an occurrence in the form of a rare process of the disease is sufficient to prevent most vascular complications and justifies the currently used corticosteroid regimens.11 Dr Rozin is concerned about the possibility of a dramatic relapse of the disease, with blindness or cerebrovascular accident, which should have been considered before the first administration (by us) of infliximab as monotherapy. We would not have given a second infusion, if the first, not impressively encouraged us to continue. Furthermore, we should emphasise that we followed up our patients closely, with a complete physical and ophthalmological evaluation and appropriate laboratory work every 2 weeks, and this should have enabled us to detect in time any undesirable occurrence.

A P Andonopoulos, N Meimaris, D Dausoss, A Bouanas, G Giannopoulos

Department of Medicine – Division of Rheumatology, University of Patras School of Medicine, Patras, Greece

Correspondence to: Professor A P Andonopoulos, Division of Rheumatology, University of Patras School of Medicine, 265 00 Rio, Patras, Greece; andonop@med.upatras.gr

References


Authors’ reply

We thank Dr Rozin for his interest in our report,1 describing the experience with anti-tumour necrosis factor α (infliximab) administration as monotherapy for giant cell arthritis (GCA), because this provides us with the opportunity to express some further thoughts on this approach.

It appears that Dr Rozin’s initial concern about the loss of response to infliximab of our two patients with GCA, has to do with the possibility of development of human anti-chimeric antibodies (HACA) in their sera. The development of such antibodies in our patients, who did not receive concomitant methotrexate (MTX) and were treated with relatively low dose infliximab, is quite likely, as this occurrence is well established as Dr Rozin indicates. However, we would like to make the following points on this matter.

Firstly, the design of our trial precluded the use of MTX because our purpose was to investigate the effectiveness of infliximab alone in GCA, and MTX has been used, albeit with questionable results, in the treatment of this disease, mainly as a steroid sparing agent.2 Secondly, we employed the usual therapy regimen with 3 mg/kg body weight of infliximab empirically, and after the initial impressive response of our patients to that dose we continued with it.

Thirdly, although the development of HACA in our patients cannot be at all sure that this influenced the clinical response of the patients to infliximab. Our point is mainly based on the results of a recent report by Wagner et al.,3 in rheumatoid patients of the ATTRACT trial, which showed that HACA were developed in 25 of 295 patients (8.5%), but their presence did not affect the proportion of patients with an American College of Rheumatology (ACR)20 or ACR50 response, after long term infliximab treatment.

Fourthly, we indicated that infliximab administration, probably in higher doses and more frequently, should be kept for refractory cases, otherwise we considered that such an approach was not cost effective. Thus we suggested that for a disease easily controlled with corticosteroids, an expensive treatment such as one employing infliximab is only justified if it proves effective in “curing” GCA, in a relatively short time, that is, five infusions at the most. In this way, the long term undesirable side effects of chronic corticosteroid administration would be avoided. Returning now to that point, after having shown that infliximab is effective in GCA (and this is, we think, an important finding of our trial), we cannot preclude its use, in combination with MTX, in the usual 3 mg/kg body weight or higher dosage, in refractory cases of the disease or where chronic corticosteroid administration is contraindicated or is not tolerated. However, appropriately designed studies using this agent in “routine” cases of GCA, probably including serum interleukin 6 in their evaluation of disease remission, is needed to answer the question whether short term infliximab treatment (five infusions), combined with MTX and even corticosteroids, is “curative.”

Finally, we agree with Dr Rozin that “self limiting disease” was not the most appropriate characterisation for GCA. This term was used because most studies have suggested that treatment with steroids is usually stopped within 2 years in most patients, although there is no evidence that such treatment reduces the duration of the disease,4 and a great deal of controversy exists.5 It has been further argued from clinical experience that partial suppression of the inflammatory process of the disease is sufficient to prevent most vascular complications and justifies the currently used corticosteroid regimens.6 Dr Rozin is concerned about the possibility of a dramatic relapse of the disease, with blindness or cerebrovascular accident, which should have been considered before the first administration (by us) of infliximab as monotherapy. We would not have given a second infusion, if the first, not impressively encouraged us to continue. Furthermore, we should emphasise that we followed up our patients closely, with a complete physical and ophthalmological evaluation and appropriate laboratory work every 2 weeks, and this should have enabled us to detect in time any undesirable occurrence.

A P Andonopoulos, N Meimaris, D Dausoss, A Bouanas, G Giannopoulos

Department of Medicine – Division of Rheumatology, University of Patras School of Medicine, Patras, Greece

Correspondence to: Professor A P Andonopoulos, Division of Rheumatology, University of Patras School of Medicine, 265 00 Rio, Patras, Greece; andonop@med.upatras.gr

References


Ultrasound detection of knee patellar enthesis

We read with interest the report by Kamel et al who highlighted the use of ultrasound (US) and magnetic resonance imaging (MRI) for the detection of patellar tendon enthesis in patients with seronegative arthropathies without typical radiographic evidence. Their work adds to the growing body of evidence supporting the clinical use of US in rheumatological practice. US has previously been shown to be better than clinical examination for the detection of enthesis.2,6 but data on MRI are more limited. The authors make interesting observations about the position of the abnormalities in the patellar tendon, when compared with the Achilles tendon, possibly relating to joint biomechanics and lines of force. However, we would like to raise a few points on what we regard as important omissions from the paper.

Firstly, the authors do not include the frequencies of the described US or the technical details of the MRI findings and do not state how the modalities correlated with each other. The authors also do not comment on the presence of bone marrow oedema adjacent to the enthesis on MRI. With regard to the plantar fascia, it has been reported that adjacent bone marrow oedema changes are more prominent than soft tissue entheseal changes.3 No data were presented on the reproducibility of either imaging technique for the detection of enthesis.

Secondly, frequent mention of “early” US findings such as calcification and fatty degeneration is made. However, no correlation with disease or symptom duration is recorded for either image modality. Similarly, no correlation between patient age and the findings was made—that is, was calcification an age related phenomenon. Control groups of normal subjects and patients without spondyloarthropathy would have strengthened the study.

Thirdly, it would also have been relevant to know if the patients had had any previous corticosteroid injections, as calcified foci are not uncommonly found around the sites of injection, sometimes lasting for many months or years. It is possible, therefore, to over diagnose enthesis if this is based on the presence of calcium deposits alone.

Lastly, the authors make no mention of power Doppler, which has recently been shown to increase specificity of the grey scale findings for the detection of enthesis.3 It would have been interesting to correlate this with the MRI findings.

In conclusion, although the findings in this report are interesting and we agree that US is a useful tool in the diagnosis of enthesis, care needs to be taken in interpreting such data when all the information has not been presented.

R J Wakefield, D McGonagle, A L Tan, A Evangelisto, P Emery
Academic Department of Musculoskeletal Medicine, First Floor, Old Nurse’s Home, General Infirmary at Leeds, Great George Street, Leeds LS1 3EJ, UK

Correspondence to: Professor P Emery; p.emery@leeds.ac.uk

References


Authors’ reply

We thank Dr Paul Emery and colleagues for their letter and we are happy that our study has stimulated useful comments. Indeed, the published “Letter” provided only a limited opportunity to describe detailed data. We were not able to publish the full text page of knee patellar enthesis because of some overlap of the data with our published study on heel enthesis.1 Table 1 summarises the findings of both ultrasound (US) and magnetic resonance imaging (MRI) examinations of enthesis in each individual case. It also shows the frequencies of these described US and MRI findings and how these imaging modalities correlated with each other. We identified bone oedema in two cases: the two patients had reactive bone oedema secondary to patellar tendon inflammation that was maximal at the entheseal insertion, indicating osteitis associated with enthesis.

As regard the comment on calcification, the US was sensitive and accurate in detecting the early development of calcific foci in the patellar tendon in 2/16 (12.5%) patients, while MRI failed to recognise their presence (please refer to the previous published figure).5 The detection of an early calcification process by US was found to be a clinically important sign because it did not correlate with the disease duration. Further, the development of calcific foci in the patellar tendon was less frequent than the calcification of Achilles tendon of heel enthesis.1,4 The two patients were aged 26 and 34 years, neither of them had a history of local steroid injection into the knee and so the calcification was not an age related phenomenon, rather it was secondary to a previous local steroid injection. We wonder how our colleagues came to the conclusion that we used the presence of calcium deposition as a clue to making a diagnosis of enthesis. This was not mentioned in our letter or in our previous reports dealing with the diagnosis of enthesis.5

The interobserver variability of sonographic readings was assessed by video recording the US examination and comparing the images obtained sequentially by three independent observers (sonographer, radiologist, and rheumatologist), who were unaware of the patient’s name or clinical diagnosis. Agreement between readers’ interpretation was statistically assessed using the weighted k ranges from 0 (no agreement beyond chance) to 1.0 (perfect agreement beyond chance). The interobserver variability was negligible and yielded an excellent coefficient of r = 0.89 (baseline), r = 0.82 US, and r = 0.74 MRI. Therefore, the presented US data were statistically significant and clinically reproducible.

We are currently combining US examination with power Doppler for some cases when we expect proliferation of synovial tissue and/ or other related soft tissue components. It was not practical to include detailed data in a “Letter”. These data deserve to be published in a separate report.

Table 1: Ultrasound and MRI findings in patients with knee enthesis

<table>
<thead>
<tr>
<th>No</th>
<th>Age</th>
<th>Sex</th>
<th>Fibrillar echo pattern</th>
<th>Tendon thickness</th>
<th>Tendon margins</th>
<th>Calcification</th>
<th>Signal intensity</th>
<th>Tendon thickness</th>
<th>Tendon margins</th>
<th>Bone oedema</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>46</td>
<td>♂</td>
<td>Preserved</td>
<td>P+D</td>
<td>Defined</td>
<td>—</td>
<td>+P+D</td>
<td>Defined</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>2</td>
<td>60</td>
<td>♂</td>
<td>Preserved</td>
<td>P+D</td>
<td>Defined</td>
<td>—</td>
<td>+P+D</td>
<td>Defined</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>3</td>
<td>56</td>
<td>♂</td>
<td>Preserved</td>
<td>P+D</td>
<td>Defined</td>
<td>—</td>
<td>+P+D</td>
<td>Defined</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>4</td>
<td>55</td>
<td>♂</td>
<td>Lost</td>
<td>P+D</td>
<td>Defined</td>
<td>—</td>
<td>+P+D</td>
<td>Defined</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>5</td>
<td>26</td>
<td>♂</td>
<td>Lost</td>
<td>P+D</td>
<td>Defined</td>
<td>—</td>
<td>+P+D</td>
<td>Defined</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>6</td>
<td>48</td>
<td>♂</td>
<td>Lost</td>
<td>P+D</td>
<td>Defined</td>
<td>—</td>
<td>+P+D</td>
<td>Defined</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>7</td>
<td>71</td>
<td>♂</td>
<td>Preserved</td>
<td>P+D</td>
<td>Defined</td>
<td>—</td>
<td>+P+D</td>
<td>Defined</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>8</td>
<td>54</td>
<td>♂</td>
<td>Lost</td>
<td>P+D</td>
<td>Defined</td>
<td>—</td>
<td>+P+D</td>
<td>Defined</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>9</td>
<td>28</td>
<td>♂</td>
<td>Lost</td>
<td>P+D</td>
<td>Defined</td>
<td>—</td>
<td>+P+D</td>
<td>Defined</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>10</td>
<td>48</td>
<td>♂</td>
<td>Preserved</td>
<td>P+D</td>
<td>Defined</td>
<td>—</td>
<td>+P+D</td>
<td>Defined</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>11</td>
<td>48</td>
<td>♂</td>
<td>Lost</td>
<td>P+D</td>
<td>Defined</td>
<td>—</td>
<td>+P+D</td>
<td>Defined</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>12</td>
<td>34</td>
<td>♂</td>
<td>Lost</td>
<td>P+D</td>
<td>Defined</td>
<td>—</td>
<td>+P+D</td>
<td>Defined</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>13</td>
<td>38</td>
<td>♂</td>
<td>Lost</td>
<td>P+D</td>
<td>Defined</td>
<td>—</td>
<td>+P+D</td>
<td>Defined</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>14</td>
<td>34</td>
<td>♂</td>
<td>Lost</td>
<td>P+D</td>
<td>Defined</td>
<td>—</td>
<td>+P+D</td>
<td>Defined</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>15</td>
<td>46</td>
<td>♂</td>
<td>Preserved</td>
<td>P+D</td>
<td>Defined</td>
<td>—</td>
<td>+P+D</td>
<td>Defined</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>16</td>
<td>38</td>
<td>♂</td>
<td>Preserved</td>
<td>P+D</td>
<td>Defined</td>
<td>—</td>
<td>+P+D</td>
<td>Defined</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

p, Proximal; D, distal; ↑, increased; +, present; −, absent.
As our colleagues mentioned in their letter, we presented interesting data that describe the anatomical and pathological variations of enthesitis in the heels and knees. We strongly believe that the US examination is a very useful and reliable procedure for the diagnosis of enthesitis of different joints.

M Kamel
Al-Azhar University, Cairo, Egypt

R Mansour, M Abbody
Dr Fahery and Almuhawwas Hospital, Alkhobar, Saudia Arabia

H Eid
Memorial University, Egypt

References


BOOK REVIEW

Rheumatology, third edition

It is a particular challenge to present a new edition of a textbook that has been praised as the “model for other textbooks” and “a departure from everything that has preceded it”. The third edition of international editors of Rheumatology has accepted this task and has succeeded brilliantly. The third edition of Rheumatology is an admirable Reference that brings together comprehensive, up to date coverage, more than 1600 full colour photographs, tables and charts, and practical clinical guidance for the practising and academic rheumatologist and arthritist related healthcare professional in a well organised, highly visual format. It is consistent in content, style, and format, and colour coded sections add to its easy and enjoyable use. Almost 300 international experts, many of them new in the author team, have contributed to this edition. They represent the entire spectrum of clinical and academic rheumatology and of biomedical, clinical, and epidemiological research. Acknowledging the immense progress in the treatment of rheumatic disease over recent years, the authors have extensively revised the section on principles of therapy and the introductory section. Almost half of the chapters have been completely rewritten and 58 chapters have been added. Essential new information is provided on basic biomedical science, clinical therapeutics, disease and outcome measurement, and patient management and rehabilitation. There is a strong focus on evidence based medicine throughout, and increased importance is given to non-drug treatment, bone disorders, management of paediatric and geriatric patients, orthopaedics, and the latest pain management techniques.

M Kamel

ACR/ARHP 68th Annual Scientific Meeting
16–21 October 2004; San Antonio, Texas, USA
Web site: www.rheumatology.org/annual/index.asp

Xth International Conference on Behcet’s Disease
27–31 October 2004; Antalya, Turkey
Contact: Congress Secretariat, Figur Congress and Organization Services Ltd. STI, Ayazmaderesi Cad. Karadut Sok. No: 7 80888 Dikilitas, Istanbul, Turkey
Tel: +90 (0212) 258 6020 Fax: +90 (0212) 258 6078 Email: behcet2004@figur.net Website: www.behcet2004.org

4th International Congress on Autoimmunity
3–7 November 2004; Budapest, Hungary
Deadline for receipt of abstracts: 20 June 2004 Contact: 4th International Congress on Autoimmunity, Kones International—Global Congress Organisers and Association Management Services, 17 rue du Cendrier, PO Box 1726, CH-1211 Geneva 1, Switzerland
Tel: +41 22 908 0488 Fax: +41 22 732 2850 Email: autoim04@kones.com Website: www.kones.com/autoim2004

8th EULAR Postgraduate Course in Rheumatology
28 November–3 December 2004; Prague, Czech Republic
Contact: EULAR Secretariat, Wittenwerstrasse 15, CH 8032 Zurich, Switzerland
Tel: +41 1 383 96 90 Fax: +41 1 383 98 10 Email: secretariat@eular.org Website: www.eular.org

FORTHCOMING EVENTS

8th EULAR Sonography Course
7–9 June 2004; Berlin, Germany
Organising Committee: Marina Backhaus, Wolfgang Schmidt Contact: Congress Organisation: Gedeon Congress Service Tel: +49-30-22488390 Fax: +49-30-22488389 Email: gedel.cm@t-online.de Website: www.eular.org

EULAR 2004
9–12 June 2004; Berlin, Germany
Contact: EULAR Secretariat Tel: +41 1 383 96 90 Fax: +41 1 383 98 10 Email: secretariat@eular.org Website: http://www.eular.org

First European Course: Capillaroscopy and Rheumatic Diseases
10–12 September 2004; Genova, Italy
Contact: Scientific Secretariat: Professor Maurizio Cutolo, Division of Rheumatology, DIMI, University of Genova, Italy
Tel: +39 02 281 72310 Fax: +39 02 281 72399 Email: edracongressi@dsmedigroup.com

Osteoarthritis Research Society International
2–5 December 2004; Chicago, USA
Contact: 17 000 Commerce Parkway, Suite C, Mt Laurel, NJ 08054, USA
Email: oarsi@oarsi.org Tel: +01 856 439 1385 or visit http://www.oarsi.org

VIIIth European Lupus Meeting
3–5 March 2005; Royal College of Physicians, London, UK
Contact: Julia Kermode, Conference organiser of the British Society of Rheumatology Email: Julia@Rheumatology.org.uk
Ultrasound detection of knee patellar enthesitis

R J Wakefield, D McGonagle, A L Tan, A Evangelisto and P Emery

Ann Rheum Dis 2004 63: 753-754

Updated information and services can be found at:
http://ard.bmj.com/content/63/6/753

These include:

References
This article cites 8 articles, 4 of which you can access for free at:
http://ard.bmj.com/content/63/6/753#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/